BMS 986177

Drug Profile

BMS 986177

Alternative Names: BMS986177

Latest Information Update: 18 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Factor IXa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Thrombosis

Most Recent Events

  • 19 Apr 2018 Bristol-Myers Squibb and Janssen plan a phase II trial for Stroke (Prevention) in second half of 2018
  • 16 Apr 2018 Bristol-Myers Squibb and Janssen Pharmaceuticals enter into a worldwide collaboration to develop and commercialise BMS 986177 for Thrombosis
  • 01 Mar 2018 Bristol-Myers Squibb initiates a phase I pharmacokinetics trial in USA (PO) (NCT02982707)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top